Correlation Between Visa and Xeris Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Visa and Xeris Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Xeris Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Visa Class A and Xeris Pharmaceuticals, you can compare the effects of market volatilities on Visa and Xeris Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Xeris Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Xeris Pharmaceuticals.

Diversification Opportunities for Visa and Xeris Pharmaceuticals

0.65

Correlation Coefficient

Visa  Xeris Pharmaceuticals

Poor diversification

The 3 months correlation between Visa and Xeris is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Xeris Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xeris Pharmaceuticals and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Xeris Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xeris Pharmaceuticals has no effect on the direction of Visa i.e., Visa and Xeris Pharmaceuticals go up and down completely randomly.

Pair Corralation between Visa and Xeris Pharmaceuticals

Taking into account the 90-day investment horizon Visa is expected to generate 2.29 times less return on investment than Xeris Pharmaceuticals. But when comparing it to its historical volatility, Visa Class A is 2.04 times less risky than Xeris Pharmaceuticals. It trades about 0.12 of its potential returns per unit of risk. Xeris Pharmaceuticals is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  286.00  in Xeris Pharmaceuticals on September 12, 2024 and sell it today you would earn a total of  67.50  from holding Xeris Pharmaceuticals or generate 23.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Visa Class A  vs.  Xeris Pharmaceuticals

Visa Class A

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Visa Class A are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Visa may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Xeris Pharmaceuticals

Risk-Adjusted Performance

11 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Xeris Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Xeris Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Visa and Xeris Pharmaceuticals

The main advantage of trading using opposite Visa and Xeris Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Xeris Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xeris Pharmaceuticals will offset losses from the drop in Xeris Pharmaceuticals' long position.

The idea behind Visa Class A and Xeris Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.